Applications

1414 – PD-L1 testing for access to Pembrolizumab for the treatment of locally advanced or metastatic NSCLC

Find out about the service or technology in this application and the medical condition it addresses. You can also view the application documents, the deadlines for providing consultation input and the outcome of the application when the MSAC process is complete.

  • Status Complete
  • Type New application
  • Pre-PASC consultation -
  • Pre-MSAC consultation -
  • Outcome Not supported

Application details

Reason for application

New MBS item.

Service or technology in this application

TImmunoHistoChemistry (IHC) test for evaluation of Programmed Cell Death 1 Ligand (PD-L1) expression to determine eligibility for treatment with Pembrolizumab.

Type: Co-dependent technology

Medical condition this application addresses

Locally advanced or metastatic NSCLC (Stage IIIb/IV).

Meetings to consider this application

  • PASC meeting: 13 August 2016
  • ESC meeting: 6 - 7 October 2016
  • MSAC meeting: 24 - 25 November 2016